NASDAQ · DBVT
Healthcare · Biotechnology
$9.55
Down-$0.25 (-2.55%)
Updated Oct 13, 2026, 6:11 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DBVT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
DBVT closed at $9.55 after 21 trading sessions, down 22.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $9.63 | $9.72 | $9.39 | $9.55 | 311.79K |
| Oct 9, 2026 | $9.62 | $9.86 | $9.43 | $9.80 | 324.06K |
| Oct 8, 2026 | $9.74 | $9.84 | $9.36 | $9.55 | 603.27K |
| Oct 7, 2026 | $9.74 | $10.05 | $9.64 | $9.77 | 535.28K |
| Oct 6, 2026 | $10.64 | $10.66 | $9.82 | $9.98 | 558.01K |
| Oct 5, 2026 | $10.35 | $10.74 | $10.2301 | $10.44 | 224.45K |
| Oct 2, 2026 | $10.92 | $11.01 | $10.47 | $10.55 | 673.3K |
| Oct 1, 2026 | $11.30 | $11.58 | $11.02 | $11.21 | 564.49K |
| Sep 30, 2026 | $11.72 | $12.21 | $11.72 | $11.76 | 400.95K |
| Sep 29, 2026 | $11.50 | $11.675 | $11.40 | $11.55 | 199.5K |
| Sep 28, 2026 | $11.56 | $12.13 | $11.53 | $11.64 | 712.95K |
| Sep 25, 2026 | $11.405 | $11.83 | $11.40 | $11.56 | 290K |
| Sep 24, 2026 | $11.95 | $12.12 | $11.27 | $11.60 | 333.46K |
| Sep 23, 2026 | $12.46 | $12.63 | $12.10 | $12.17 | 377.51K |
| Sep 22, 2026 | $12.03 | $12.73 | $11.925 | $12.63 | 282K |
| Sep 21, 2026 | $12.31 | $12.31 | $12.00 | $12.10 | 131.43K |
| Sep 18, 2026 | $12.59 | $12.59 | $12.14 | $12.35 | 137.64K |
| Sep 17, 2026 | $12.22 | $12.615 | $12.22 | $12.51 | 158.77K |
| Sep 16, 2026 | $12.20 | $12.21 | $11.75 | $11.79 | 159.08K |
| Sep 15, 2026 | $12.20 | $12.2505 | $11.695 | $11.76 | 175.07K |
| Sep 14, 2026 | $12.20 | $12.62 | $11.92 | $12.35 | 269.58K |
The latest Smart Investors Daily articles mentioning DBVT.
Company
Market Activity
Research & News
DBVT research
Company profile and research snapshot.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Jun 16, 2024 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Mar 14, 2024 | SOCIETE GENERALE | Buy | — |
| Mar 13, 2024 | SOCIETE GENERALE | Buy | — |
| Dec 19, 2023 | PORTZAMPARC BNP PARIBAS | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 30, 2026
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsThe BLA is supported by the results from the successful Phase 3 VITESSE trial –
Yahoo · Sep 29, 2026
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, tod
Yahoo · Sep 24, 2026
European equities traded in the US as American depositary receipts were tracking slightly lower Thur
Yahoo · Sep 17, 2026
European equities traded in the US as American depositary receipts were rising sharply late Thursday
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DBVT.
